Recent Alzheimer’s Studies and News

Category: Alzheimer's | Memory Care | News

A hand holding a purple ribbon to raise Alzheimer's awareness.

Alzheimer’s disease, a progressive neurological disorder that affects memory, cognitive function, and behavior, is a growing health concern worldwide. Discovered in 1906, Alzheimer’s is now the seventh leading cause of death in the United States. As researchers continue to delve into the complexities of this devastating condition, recent studies have shed light on promising new findings and developments. In this blog post, we will explore the latest breakthroughs in Alzheimer’s news and research and discuss how Haven Health, a leading healthcare provider, is prepared to support individuals and families affected by this disease.

What is Alzheimer’s?

To lay the groundwork for discussing recent advancements in Alzheimer’s research, let’s first familiarize ourselves with the fundamental aspects of this devastating disease. Alzheimer’s typically affects older adults and is characterized by the accumulation of abnormal protein deposits, known as beta-amyloid plaques and twisted fibers called tau tangles in the brain. Over the course of several years, the accumulation of amyloid plaques and tau tangles can eventually lead to the initiation of an inflammatory response. These protein formations disrupt the normal functioning of brain cells and lead to the progressive destruction of brain cells and the deterioration of cognitive abilities. 

Learn more about Alzheimer’s memory care at Haven Health

What is the latest news about Alzheimer’s?

Evidence from an Alzheimer’s study published in the Harvard Gazette indicates that there have been significant developments in Alzheimer’s research. The study discusses the findings of a clinical trial on the drug Lacenemab, which has shown promising signs of slowing the cognitive decline associated with Alzheimer’s disease. Lecanemab is a monoclonal antibody that targets amyloid proteins.

The study, called Clarity AD, demonstrated a disease-modifying effect of Lecanemab, marking a significant advancement in Alzheimer’s treatment. Previous trials targeting amyloid proteins had yielded unfavorable results, leading to debates about its significance in the disease process. However, the Clarity AD trial provided evidence of a disease-modifying effect through amyloid removal. Additionally, the study showed that Lecanemab not only reduced levels of amyloid but also tau and neurodegeneration markers in the blood and cerebrospinal fluid. 

The magnitude of the effect observed in the trial indicated a substantial benefit. Lecanemab slowed the rate of cognitive and functional decline by approximately 25% to 35% percent over an 18-month period compared to a placebo. These results have sparked optimism and hope among patients and their families, although it is essential to note that the drug is not a cure. Overall, the findings from the Clarity AD trial and ongoing research efforts suggest that we are entering a new era in Alzheimer’s treatment, providing hope to patients and driving optimism in the field. 

Can Alzheimer’s be cured?

There is currently no known cure for Alzheimer’s disease. While there have been significant advancements in research and treatment options, finding a definitive cure for Alzheimer’s remains a challenge. 

Several approaches are being explored to manage and slow the progression of the disease. Medications are available to help manage the symptoms and improve the quality of life for individuals with Alzheimer’s. These medications can provide temporary relief of symptoms but do not cure the underlying disease. 

It is important to note that ongoing research is being conducted as well as clinical trials aiming to develop potential cures or disease-modifying treatments for Alzheimer’s. Some of the latest developments have shown promising results in slowing the cognitive decline associated with Alzheimer’s. However, it is crucial to continue advancing scientific understanding and conducting rigorous research to find effective therapies for this complex disease.

How can Haven Health help?

A hand holding a purple ribbon to raise Alzheimer's awareness.

Haven Health offers memory care services for individuals living with Alzheimer’s, dementia, and other memory-related conditions. Memory care services at Haven Health are designed to provide a safe and supportive environment for residents that promotes their overall well-being. 

Memory care at Haven Health focuses on personalized care that is tailored to meet the individual needs of each resident. Our staff is expertly trained to understand the challenges individuals with memory loss face and provide the support and specialized care they need. 

In addition to providing essential care services, Haven Health emphasizes engaging activities that promote cognitive stimulation and social interaction. The goal is to enhance residents’ quality of life and preserve their cognitive abilities as much as possible. 

We are dedicated to providing a supportive and compassionate environment for all of our residents. Memory care services are centered around promoting dignity, independence, and a sense of belonging and purpose. Families will have peace of mind knowing their loved ones are receiving the specialized care they need in a secure and caring community.  

Contact us today to learn more about our personalized memory care services

Alzheimer’s disease and other forms of dementia continue to present significant challenges for individuals and their families. However, there have been exciting advancements in research and medical understanding of these conditions, allowing for the development of more effective treatments and care approaches. As new developments in Alzheimer’s treatment and understanding continue to unfold, Haven Health remains dedicated to staying updated and providing the highest level of care.


Alzheimer’s Association. (2023). Treatments

Balch, B. (2023). Recent breakthroughs in Alzheimer’s research provide hope for patients. 

Powell, A. (2023). Start of New Era for Alzheimer’s Treatment.